Related Experiment Video

Updated: Jun 18, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Transforming growth factor-beta as a treatment target in renal diseases

Noboru Fukuda1, Yoshiko Tahira, Hiroyuki Matsuda

  • 1Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. fukudan@med.nihon-u.ac.jp

Journal of Nephrology
|December 8, 2009
PubMed

Insights

New gene silencers targeting transforming growth factor-beta (TGF-beta) show promise for treating kidney diseases like glomerulosclerosis. These novel therapies effectively reduced renal injury in hypertensive rat models.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biotechnology

Background:

  • Transforming growth factor-beta (TGF-beta) is implicated in the pathogenesis of various renal diseases, including glomerulosclerosis and mesangioproliferative glomerulonephritis.
  • TGF-beta promotes mesangial cell proliferation, extracellular matrix production, and epithelial-mesenchymal transformation, contributing to renal injury.
  • Current medical treatments are insufficient for halting progressive renal diseases.

Purpose of the Study:

  • To investigate the therapeutic potential of novel TGF-beta-targeted gene silencers for ameliorating renal injury.
  • To evaluate the efficacy of ribozymes and pyrrole-imidazole polyamide as gene silencers for TGF-beta in a preclinical model.

Main Methods:

  • Development of ribozymes and a pyrrole-imidazole polyamide targeting TGF-beta.
  • Administration of these gene silencers in a rat model of hypertensive renal injury.
  • Assessment of the amelioration of renal injury following treatment.

Main Results:

  • The developed ribozymes and pyrrole-imidazole polyamide effectively targeted TGF-beta.
  • These novel gene silencers significantly ameliorated renal injury in hypertensive rats.
  • The findings suggest a potential new therapeutic strategy for progressive kidney diseases.

Conclusions:

  • Targeting TGF-beta with novel gene silencing technologies offers a promising therapeutic approach for renal diseases.
  • Ribozymes and pyrrole-imidazole polyamide demonstrate significant potential in preclinical models of kidney injury.
  • Further research is warranted to translate these findings into clinical applications for patients with progressive renal conditions.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...